Business
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
SAN CARLOS, Calif., February 26, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":28492,"height":5743,"url":"https://media.zenfs.com/en/business-wire.com/6abf9e7bd2ef1cc158423d8e1b54f5ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dELfoFZPRcrcyMpCgX8OoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6abf9e7bd2ef1cc158423d8e1b54f5ee","width":960,"height":194},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/erZMRa9H2QSI0B6mMRAXPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6abf9e7bd2ef1cc158423d8e1b54f5ee","width":1200,"height":242}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods","length":145,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periods","length":163,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Diluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full year","length":204,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion","length":69,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":581,"olType":false},{"type":"text","content":"SAN CARLOS, Calif., February 26, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.","length":244,"tagName":"p"},{"type":"text","content":""These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical development and manufacturing and one of the industry’s deepest and most differentiated pipelines," said John V. Oyler, Co-Founder, Chairman and...